Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This three-part, Phase 1 protocol will be the first clinical study of AB-836. Parts 1 and 2
will be a Phase 1a SAD/MAD of AB-836 in healthy adult subjects. Part 3 will be a Phase 1b
dose-ranging assessment of AB-836 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.